The shortest path is not the one you know: Application of biological network resources in precision oncology research

Mutagenesis

Volumn 30, Issue 2, 2015, Pages 191-204

  Kuperstein, Inna ^a,b   Grieco, Luca ^a,b,c,d,e,f   Cohen, David P A ^a,b   Thieffry, Denis ^c,d,e   Zinovyev, Andrei ^a,b   Barillot, Emmanuel ^a,b  

^a INSERM U900   (France)

^b PSL RESEARCH UNIVERSITY   (France)

^c PSL RESEARCH UNIVERSITY   (France)

^d CNRS   (France)

^e INSERM   (France)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROTEIN KINASE B; SMALL INTERFERING RNA; TRANSCRIPTOME;

BLADDER CANCER; BREAST CANCER; CANCER GROWTH; CANCER RESEARCH; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CLINICAL PRACTICE; DNA REPAIR; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR GENE; BIOLOGY; GENETICS; INTERNET; METABOLISM; MUTATION; NEOPLASM;

COMPUTATIONAL BIOLOGY; GENE EXPRESSION; HUMANS; INTERNET; MUTATION; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84935094294     PISSN: 02678357     EISSN: 14643804     Source Type: Journal    
DOI: 10.1093/mutage/geu078     Document Type: Review

References (79)

1. Berns, K. and Bernards, R. (2012) Understanding resistance to targeted cancer drugs through loss of function genetic screens. Drug Resist. Updat., 15, 268-275.
2. Garraway, L. A., Verweij, J. and Ballman, K. V. (2013) Precision oncology: an overview. J. Clin. Oncol., 31, 1803-1805.
3. Sun, C., Wang, L., Huang, S., et al. (2014) Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature, 508, 118-122.
4. Bader, G. D., Cary, M. P. and Sander, C. (2006) Pathguide: a pathway resource list. Nucleic Acids Res., 34, D504-D506.
5. Klingström, T. and Plewczynski, D. (2011) Protein-protein interaction and pathway databases, a graphical review. Brief. Bioinform., 12, 702-713.
6. Ooi, H. S., Schneider, G., Lim, T. T., Chan, Y. L., Eisenhaber, B. and Eisen-haber, F. (2010) Biomolecular pathway databases. Methods Mol. Biol., 609, 129-144.
7. Milanowska, K., Krwawicz, J., Papaj, G., Kosinski, J., Poleszak, K., Lesiak, J., Osinska, E., Rother, K. and Bujnicki, J. M. (2011) REPAIRtoire-a database of DNA repair pathways. Nucleic Acids Res., 39, D788-D792.
8. Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H. and Kanehisa, M. (1999) KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res., 27, 29-34.
9. Nishimura, D. (2001) BioCarta. Biotech. Softw. Internet Rep., 2, 117-120.
10. Ashburner, M., Ball, C. A., Blake, J. A., et al. (2000) Gene ontology: tool for the unifcation of biology. The Gene Ontology Consortium. Nat. Genet., 25, 25-29.
11. Subramanian, A., Tamayo, P., Mootha, V. K., et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profles. Proc. Natl Acad. Sci. U. S. A., 102, 15545-15550.
12. Bauer-Mehren, A., Furlong, L. I. and Sanz, F. (2009) Pathway databases and tools for their exploitation: benefts, current limitations and challenges. Mol. Syst. Biol., 5, 290.
13. Franceschini, A., Szklarczyk, D., Frankild, S., et al. (2013) STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res., 41, D808-D815.
14. Chatr-Aryamontri, A., Breitkreutz, B. J., Heinicke, S., et al. (2013) The BioGRID interaction database: 2013 update. Nucleic Acids Res., 41, D816-D823.
15. Lee, I., Blom, U. M., Wang, P. I., Shim, J. E. and Marcotte, E. M. (2011) Prioritizing candidate disease genes by network-based boosting of genome-wide association data. Genome Res., 21, 1109-1121.
16. Cerami, E. G., Gross, B. E., Demir, E., Rodchenkov, I., Babur, O., Anwar, N., Schultz, N., Bader, G. D. and Sander, C. (2011) Pathway Commons, a web resource for biological pathway data. Nucleic Acids Res., 39, D685-D690.
17. Kamburov, A., Pentchev, K., Galicka, H., Wierling, C., Lehrach, H. and Herwig, R. (2011) ConsensusPathDB: toward a more complete picture of cell biology. Nucleic Acids Res., 39, D712-D717.
18. Keshava Prasad, T. S., Goel, R., Kandasamy, K., et al. (2009) Human Protein Reference Database-2009 update. Nucleic Acids Res., 37, D767-D772.
19. Paz, A., Brownstein, Z., Ber, Y., et al. (2011) SPIKE: a database of highly curated human signaling pathways. Nucleic Acids Res., 39, D793-D799.
20. Gough, N. R. (2002) Science's signal transduction knowledge environment: the connections maps database. Ann. N. Y. Acad. Sci., 971, 585-587.
21. Croft, D., Mundo, A. F., Haw, R., et al. (2014) The Reactome pathway knowledgebase. Nucleic Acids Res., 42, D472-D477.
22. Romero, P., Wagg, J., Green, M. L., Kaiser, D., Krummenacker, M. and Karp, P. D. (2005) Computational prediction of human metabolic pathways from the complete human genome. Genome Biol., 6, R2.
23. Mi, H. and Thomas, P. (2009) PANTHER pathway: an ontology-based pathway database coupled with data analysis tools. Methods Mol. Biol., 563, 123-140.
24. Kelder, T., van Iersel, M. P., Hanspers, K., Kutmon, M., Conklin, B. R., Evelo, C. T. and Pico, A. R. (2012) WikiPathways: building research communities on biological pathways. Nucleic Acids Res., 40, D1301-D1307.
25. D'Antonio, M., Pendino, V., Sinha, S. and Ciccarelli, F. D. (2012) Network of Cancer Genes (NCG 3.0): integration and analysis of genetic and network properties of cancer genes. Nucleic Acids Res., 40, D978-D983.
26. Schaefer, C. F., Anthony, K., Krupa, S., Buchoff, J., Day, M., Hannay, T. and Buetow, K. H. (2009) PID: the Pathway Interaction Database. Nucleic Acids Res., 37, D674-D679.
27. Hanahan, D. and Weinberg, R. A. (2011) Hallmarks of cancer: the next generation. Cell, 144, 646-674.
28. Kuperstein, I., Cohen, D. P., Pook, S., Viara, E., Calzone, L., Barillot, E. and Zinovyev, A. (2013) NaviCell: a web-based environment for navigation, curation and maintenance of large molecular interaction maps. BMC Syst. Biol., 7, 100.
29. Barabási, A. L., Gulbahce, N. and Loscalzo, J. (2011) Network medicine: a network-based approach to human disease. Nat. Rev. Genet., 12, 56-68.
30. Huang da, W., Sherman, B. T. and Lempicki, R. A. (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res., 37, 1-13.
31. Mitrea, C., Taghavi, Z., Bokanizad, B., Hanoudi, S., Tagett, R., Donato, M., Voichita, C. and Draghici, S. (2013) Methods and approaches in the topology-based analysis of biological pathways. Front. Physiol., 4, 278.
32. Tomfohr, J., Lu, J. and Kepler, T. B. (2005) Pathway level analysis of gene expression using singular value decomposition. BMC Bioinformatics, 6, 225.
33. Levine, D. M., Haynor, D. R., Castle, J. C., Stepaniants, S. B., Pellegrini, M., Mao, M. and Johnson, J. M. (2006) Pathway and gene-set activation measurement from mRNA expression data: the tissue distribution of human pathways. Genome Biol., 7, R93.
34. Bild, A. H., Yao, G., Chang, J. T., et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature, 439, 353-357.
35. Köhler, S., Bauer, S., Horn, D. and Robinson, P. N. (2008) Walking the interactome for prioritization of candidate disease genes. Am. J. Hum. Genet., 82, 949-958.
36. Vanunu, O., Magger, O., Ruppin, E., Shlomi, T. and Sharan, R. (2010) Associating genes and protein complexes with disease via network propagation. PLoS Comput. Biol., 6, e1000641.
37. Pujana, M. A., Han, J. D., Starita, L. M., et al. (2007) Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat. Genet., 39, 1338-1349.
38. Hofree, M., Shen, J. P., Carter, H., Gross, A. and Ideker, T. (2013) Network-based stratifcation of tumor mutations. Nat. Methods, 10, 1108-1115.
39. Wang, K., Li, M. and Hakonarson, H. (2010) Analysing biological pathways in genome-wide association studies. Nat. Rev. Genet., 11, 843-854.
40. Reimand, J. and Bader, G. D. (2013) Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers. Mol. Syst. Biol., 9, 637.
41. Pinna, G., Araujo, N., Morozova, N. and Harel-Bellan, A. (2012) Analysis of the growth control network specifc for human lung adenocarcinoma cells. Math. Model. Nat. Phenom., 7, 337-368.
42. Krämer, A., Green, J., Pollard, J., Jr and Tugendreich, S. (2014) Causal analysis approaches in ingenuity pathway analysis. Bioinformatics, 30, 523-530.
43. Kairov, U., Karpenyuk, T., Ramanculov, E. and Zinovyev, A. (2012) Network analysis of gene lists for fnding reproducible prognostic breast cancer gene signatures. Bioinformation, 8, 773-776.
44. Balbin, O. A., Prensner, J. R., Sahu, A., et al. (2013) Reconstructing tar-getable pathways in lung cancer by integrating diverse omics data. Nat. Commun., 4, 2617.
45. Nibbe, R. K., Koyutürk, M. and Chance, M. R. (2010) An integrative-omics approach to identify functional sub-networks in human colorectal cancer. PLoS Comput. Biol., 6, e1000639.
46. Chuang, H. Y., Lee, E., Liu, Y. T., Lee, D. and Ideker, T. (2007) Network-based classifcation of breast cancer metastasis. Mol. Syst. Biol., 3, 140.
47. Gehlenborg, N., O'Donoghue, S. I., Baliga, N. S., et al. (2010) Visualization of omics data for systems biology. Nat. Methods, 7, S56-S68.
48. Huan, T., Wu, X. and Chen, J. Y. (2010) Systems biology visualization tools for drug target discovery. Expert Opin. Drug Discov., 5, 425-439.
49. Lawrence, M. S., Stojanov, P., Polak, P., et al. (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature, 499, 214-218.
50. Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., Jr and Kinzler, K. W. (2013) Cancer genome landscapes. Science, 339, 1546-1558.
51. Burgess, A. W., Faux, M. C., Layton, M. J. and Ramsay, R. G. (2011) Wnt signaling and colon tumorigenesis-a view from the periphery. Exp. Cell Res., 317, 2748-2758.
52. Perchiniak, E. M. and Groden, J. (2011) Mechanisms regulating microtu-bule binding, DNA replication, and apoptosis are controlled by the intestinal tumor suppressor APC. Curr. Colorectal Cancer Rep., 7, 145-151.
53. Ashworth, A. and Bernards, R. (2010) Using functional genetics to understand breast cancer biology. Cold Spring Harb. Perspect. Biol., 2, a003327.
54. Turner, N. C., Lord, C. J., Iorns, E., Brough, R., Swift, S., Elliott, R., Rayter, S., Tutt, A. N. and Ashworth, A. (2008) A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J., 27, 1368-1377.
55. Ware, K. E., Marshall, M. E., Heasley, L. R., Marek, L., Hinz, T. K., Her-cule, P., Helfrich, B. A., Doebele, R. C. and Heasley, L. E. (2010) Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PLoS One, 5, e14117.
56. Fedorov, Y., Anderson, E. M., Birmingham, A., Reynolds, A., Karpilow, J., Robinson, K., Leake, D., Marshall, W. S. and Khvorova, A. (2006) Off-target effects by siRNA can induce toxic phenotype. RNA, 12, 1188-1196.
57. TCGA Network. (2012) Comprehensive molecular portraits of human breast tumours. Nature, 490, 61-70.
58. Scherbakov, A. M., Andreeva, O. E., Shatskaya, V. A. and Krasil'nikov, M. A. (2012) The relationships between snail1 and estrogen receptor signaling in breast cancer cells. J. Cell. Biochem., 113, 2147-2155.
59. Bianchini, G., Pusztai, L., Karn, T., et al. (2013) Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. Breast Cancer Res., 15, R86.
60. Zeng, Q., Zhang, P., Wu, Z., et al. (2014) Quantitative proteomics reveals ER-alpha involvement in CD146-induced epithelial-mesenchymal transition in breast cancer cells. J Proteomics, 103, 153-169.
61. Wan, R., Wu, J., Baloue, K. K. and Crowe, D. L. (2013) Regulation of the Nijmegen breakage syndrome 1 gene NBS1 by c-myc, p53 and coacti-vators mediates estrogen protection from DNA damage in breast cancer cells. Int. J. Oncol., 42, 712-720.
62. Tobin, L. A., Robert, C., Nagaria, P., et al. (2012) Targeting abnormal DNA repair in therapy-resistant breast cancers. Mol. Cancer Res., 10, 96-107.
63. Grieco, L., Calzone, L., Bernard-Pierrot, I., Radvanyi, F., Kahn-Perlès, B. and Thieffry, D. (2013) Integrative modelling of the infuence of MAPK network on cancer cell fate decision. PLoS Comput. Biol., 9, e1003286.
64. Grieco, L. (2013) Integrative modelling and analysis of MAPK network deregulations in human cancers. PhD Thesis. Aix-Marseille University.
65. Vera-Licona, P., Bonnet, E., Barillot, E. and Zinovyev, A. (2013) OCSANA: optimal combinations of interventions from network analysis. Bioinfor-matics, 29, 1571-1573.
66. Zinovyev, A., Viara, E., Calzone, L. and Barillot, E. (2008) BiNoM: a cytoscape plugin for manipulating and analyzing biological networks. Bioinformatics, 24, 876-877.
67. Bonnet, E., Calzone, L., Rovera, D., Stoll, G., Barillot, E. and Zinovyev, A. (2013) BiNoM 2.0, a cytoscape plugin for accessing and analyzing pathways using standard systems biology formats. BMC Syst. Biol., 7, 18.
68. Bonnet, E., Calzone, L., Rovera, D., Stoll, G., Barillot, E. and Zinovyev, A. (2013) Practical use of BiNoM: a biological network manager software. Methods Mol. Biol., 1021, 127-146.
69. Stransky, N., Vallot, C., Reyal, F., et al. (2006) Regional copy number-independent deregulation of transcription in cancer. Nat. Genet., 38, 1386-1396.
70. Harris, L. D., De La Cerda, J., Tuziak, T., Rosen, D., Xiao, L., Shen, Y., Sabichi, A. L., Czerniak, B. and Grossman, H. B. (2008) Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microar-ray. Mol. Carcinog., 47, 678-685.
71. Askham, J. M., Platt, F., Chambers, P. A., Snowden, H., Taylor, C. F. and Knowles, M. A. (2010) AKT1 mutations in bladder cancer: identifcation of a novel oncogenic mutation that can co-operate with E17K. Oncogene, 29, 150-155.
72. Ching, C. B. and Hansel, D. E. (2010) Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway. Lab. Invest., 90, 1406-1414.
73. Downward, J. (2003) Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer, 3, 11-22.
74. Cakir, M. and Grossman, A. B. (2009) Targeting MAPK (Ras/ERK) and PI3K/Akt pathways in pituitary tumorigenesis. Expert Opin. Ther. Targets, 13, 1121-1134.
75. Zachos, I., Konstantinopoulos, P. A., Tzortzis, V., Gravas, S., Karatzas, A., Karamouzis, M. V., Melekos, M. and Papavassiliou, A. G. (2010) Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise. Expert Opin. Investig. Drugs, 19, 875-887.
76. Lacroix, L., Boichard, A., André, F. and Soria, J. C. (2014) Genomes in the clinic: the Gustave Roussy Cancer Center experience. Curr. Opin. Genet. Dev., 24, 99-106.
77. Kaufman, H. L. (2014) Melanoma as a model for precision medicine in oncology. Lancet Oncol., 15, 251-253.
78. Raphael, B. J., Dobson, J. R., Oesper, L. and Vandin, F. (2014) Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine. Genome Med., 6, 5.
79. Barillot, E., Calzone, L., Hupe, P., Vert, J.-P., and Zinovyev, A. (2012) Computational Systems Biology of Cancer. CRC Press, Boca Raton, FL, USA.